Neumora Therapeutics, Inc Common Stock
Yahoo Finance • 7 months ago
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics, Inc. NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response NMRA-511 was generally... Full story
Yahoo Finance • last year
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single ascending d... Full story
Yahoo Finance • last year
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical milestones and advancing multiple precli... Full story
Yahoo Finance • last year
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two... Full story
Yahoo Finance • last year
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.... Full story
